DE69621799T2 - USE OF GABAPENTIN AND ITS DERIVATIVES IN THE TREATMENT OF MANIA AND BIPOLAR DISORDERS - Google Patents

USE OF GABAPENTIN AND ITS DERIVATIVES IN THE TREATMENT OF MANIA AND BIPOLAR DISORDERS

Info

Publication number
DE69621799T2
DE69621799T2 DE69621799T DE69621799T DE69621799T2 DE 69621799 T2 DE69621799 T2 DE 69621799T2 DE 69621799 T DE69621799 T DE 69621799T DE 69621799 T DE69621799 T DE 69621799T DE 69621799 T2 DE69621799 T2 DE 69621799T2
Authority
DE
Germany
Prior art keywords
treatment
mania
gabapentin
derivatives
bipolar disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69621799T
Other languages
German (de)
Other versions
DE69621799D1 (en
Inventor
Chandra Pande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE69621799D1 publication Critical patent/DE69621799D1/en
Application granted granted Critical
Publication of DE69621799T2 publication Critical patent/DE69621799T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention is a novel therapeutic use of gabapentin, its derivatives, and the pharmaceutical salts thereof. The compounds are useful in the treatment of mania in all its various forms whether acute or chronic, single or recurrent, and whether or not it is associated with depression. The invention further includes the treatment of bipolar disorder.
DE69621799T 1995-05-15 1996-04-26 USE OF GABAPENTIN AND ITS DERIVATIVES IN THE TREATMENT OF MANIA AND BIPOLAR DISORDERS Expired - Fee Related DE69621799T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/440,570 US5510381A (en) 1995-05-15 1995-05-15 Method of treatment of mania and bipolar disorder
PCT/US1996/005898 WO1996036328A1 (en) 1995-05-15 1996-04-26 A method of treatment of mania and bipolar disorder

Publications (2)

Publication Number Publication Date
DE69621799D1 DE69621799D1 (en) 2002-07-18
DE69621799T2 true DE69621799T2 (en) 2003-01-02

Family

ID=23749281

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69621799T Expired - Fee Related DE69621799T2 (en) 1995-05-15 1996-04-26 USE OF GABAPENTIN AND ITS DERIVATIVES IN THE TREATMENT OF MANIA AND BIPOLAR DISORDERS

Country Status (19)

Country Link
US (1) US5510381A (en)
EP (1) EP0825857B1 (en)
JP (1) JPH11505244A (en)
AT (1) ATE218857T1 (en)
AU (1) AU702435B2 (en)
CA (1) CA2215923C (en)
CZ (1) CZ288072B6 (en)
DE (1) DE69621799T2 (en)
DK (1) DK0825857T3 (en)
EE (1) EE03420B1 (en)
ES (1) ES2177783T3 (en)
GE (1) GEP20002014B (en)
HU (1) HUP9802087A3 (en)
NO (1) NO315967B1 (en)
NZ (1) NZ307366A (en)
PT (1) PT825857E (en)
SK (1) SK281982B6 (en)
WO (1) WO1996036328A1 (en)
ZA (1) ZA963826B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
CA2255652C (en) 1996-07-24 2004-07-13 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
AU9318398A (en) 1997-10-07 1999-04-27 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
JP3756761B2 (en) 1997-10-27 2006-03-15 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Cyclic amino acids and their derivatives useful as pharmaceuticals
EP1077692B1 (en) 1998-05-15 2004-07-28 Warner-Lambert Company LLC Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
BR9910494B1 (en) * 1998-05-15 2011-11-01 solid compositions containing gamma-aminobutyric acid derivatives and process for their preparation.
KR20010043831A (en) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Conformationally Constrained Amino Acid Compounds Having Affinity for the Alpha2delta Subunit of a Calcium Channel
WO2000002546A2 (en) * 1998-07-09 2000-01-20 Warner-Lambert Company Use of caba-analogues for treating insomnia
AU762599B2 (en) * 1998-10-16 2003-06-26 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
WO2000073300A1 (en) * 1999-06-02 2000-12-07 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
AU6699201A (en) * 2000-06-16 2002-01-02 Teva Pharma Stable gabapentin having ph within a controlled range
HUP0300833A3 (en) * 2000-06-26 2009-08-28 Warner Lambert Co Gabapentin analogues for treating sleep disorders
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
ITMI20012750A1 (en) 2001-12-21 2003-06-21 Procos Spa PROCESS FOR THE PRODUCTION OF 1- (AMINOMETHYL) -CYCLOHEXYL-ACETIC ACID IN PURE FORM
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
IN2012MN02923A (en) 2010-06-01 2015-06-05 Rubicon Res Private Ltd
EP2923694B1 (en) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
US11670410B1 (en) * 2022-04-13 2023-06-06 Green Sky Creations LLC Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (en) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression

Also Published As

Publication number Publication date
CZ355897A3 (en) 1998-02-18
SK281982B6 (en) 2001-09-11
EP0825857A1 (en) 1998-03-04
EP0825857B1 (en) 2002-06-12
DE69621799D1 (en) 2002-07-18
CZ288072B6 (en) 2001-04-11
CA2215923A1 (en) 1996-11-21
HUP9802087A2 (en) 1998-12-28
NO315967B1 (en) 2003-11-24
NO975234D0 (en) 1997-11-14
DK0825857T3 (en) 2002-09-30
AU702435B2 (en) 1999-02-18
MX9707269A (en) 1997-11-29
US5510381A (en) 1996-04-23
SK152897A3 (en) 1999-05-07
HUP9802087A3 (en) 1999-08-30
NZ307366A (en) 1999-10-28
EE03420B1 (en) 2001-06-15
ZA963826B (en) 1996-11-21
JPH11505244A (en) 1999-05-18
ES2177783T3 (en) 2002-12-16
WO1996036328A1 (en) 1996-11-21
AU5668996A (en) 1996-11-29
NO975234L (en) 1997-11-14
GEP20002014B (en) 2000-04-10
EE9700302A (en) 1998-06-15
CA2215923C (en) 2001-10-09
PT825857E (en) 2002-11-29
ATE218857T1 (en) 2002-06-15

Similar Documents

Publication Publication Date Title
DE69621799D1 (en) USE OF GABAPENTIN AND ITS DERIVATIVES IN THE TREATMENT OF MANIA AND BIPOLAR DISORDERS
CY1106020T1 (en) USE OF CABA ANALOGUES FOR THE INDUSTRIAL MANUFACTURE OF A DRUG FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDERS
ATE142877T1 (en) MELATONINE DERIVATIVES FOR THE TREATMENT OF SLEEP DISORDERS AND FOR PRE-ANESTHESIA
DE69331605D1 (en) USE OF PHENSERIN FOR THE PRODUCTION OF MEDICINES FOR TREATING COGNITIVE DISORDERS
DE69631478D1 (en) USE OF VITAMIN D4 DERIVATIVES FOR THE TREATMENT OF SKIN DISEASES
CY1106155T1 (en) USE OF 3-BENZOPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF AMPHIBLISTROID DISORDERS
ATE119770T1 (en) USE OF ACETYL L-CARNITINE FOR THE THERAPEUTIC TREATMENT OF COMA.
RU94040886A (en) Use of melatonine derivatives for sleep disturbance treatment, pharmaceutical composition
ATE235915T1 (en) TREATMENT OF HEMORRHAGIC VIRUS FEVER WITH PROTEIN C
DE69309790D1 (en) Cyclopentane perhydrophenanthrene-17-beta (3-furyl) -3 derivatives and pharmaceutical preparations thereof, for the treatment of cardiovascular diseases
DE69621786T2 (en) AMINOTETRAL IN DERIVATIVE FOR THE TREATMENT OF HEART CIRCULAR DISEASE
ATE261724T1 (en) ANTICONVULSIVE DERIVATIVES FOR THE TREATMENT OF POST-TRAAUMATIC STRESS DISEASES
DE59708511D1 (en) USE OF 7- (1-AMINOMETHYL-2-OXA-7-AZA-BICYCLO 3.3.0] OCT-7-YL) -CHINOLONCARBOXYLIC ACID AND -NAPHTHYRIDON-CARBONIC ACID DERIVATIVES FOR THE THERAPY OF HELICOBACTER-PYLOROXIDIZED INGENATIONALIZED INGENATIONAL ADHESIVES
DE59712344D1 (en) Use of peptidic bradykinin antagonists for the preparation of medicaments
DE59609977D1 (en) TRAPIDIL FOR USE IN THE THERAPY OF IMMUNO-MODULATABLE INFLUENCES
DE69300037T2 (en) Use of bucillamine in the manufacture of a medicament for the treatment of cystinuria.
NO953003L (en) Use of ifenprodil and its diastereoisomers for the preparation of medical preparations
DE69807586D1 (en) Use of an alkylenedioxybenzene derivative for the treatment of circadian sleep disorders
DE68906028T2 (en) USE OF ACETYL-D-CARNITIN FOR THE THERAPEUTIC TREATMENT OF GLAUCOMA.
ATE88090T1 (en) USE OF ACETYL-D-CARNITINE IN THE THERAPEUTIC TREATMENT OF GLAUCOMA.
ATE91886T1 (en) PREPARATION FOR THE TREATMENT OF ERECTIONAL DISORDERS.
ES2127133B1 (en) USE OF 2,5-DIHYDROXYBENZENOSPHONE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES INTENDED FOR THE TREATMENT AND PREVENTION OF ALZHEIMER DISEASE.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee